Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy s...

por Becker, R H A, Stechl, J, Msihid, J, Kapitza, C
Publicado 2014

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

por Steinstraesser, A, Schmidt, R, Bergmann, K, Dahmen, R, Becker, R H A
Publicado 2014

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

por Becker, R H A, Nowotny, I, Teichert, L, Bergmann, K, Kapitza, C
Publicado 2015

Radio and X-ray bright AGN: the ROSAT - FIRST correlation

por Brinkmann, W, Laurent-Mühleisen, S A, Voges, W, Siebert, J, Becker, R H, Brotherton, M S, White, R L, Gregg, M D
Publicado 2000

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

por Shiramoto, M, Eto, T, Irie, S, Fukuzaki, A, Teichert, L, Tillner, J, Takahashi, Y, Koyama, M, Dahmen, R, Heise, T, Becker, R H A
Publicado 2015